Corcept Therapeutics CORT Accrued settlement related to Melucci litigation (Note 10)

Discontinued — last reported Q4 '25

Accrued settlement related to Melucci litigation (Note 10) at other companies

MastercardMA

-$461M-487%

Krystal Biotech, Inc.KRYS

$0+100%

McKessonMCK

$5.1B-9.2%

Service Corporation InternationalSCI

$19.05M+38.1%

Altria GroupMO

$659M-2.8%

CoStar GroupCSGP

$99M+4.2%

Other financials

Income statement

See full

Revenue$164.9M+4.9%

Gross profit$162.0M+4.7%

Operating income-$49.6M-1,552%

Net income-$31.8M-255%

EPS (diluted)-$0.30-276%

Balance sheet

See full

Cash & equivalents$110.0M+21.1%

Total debt$9.6M+41.0%

Total equity$638.0M-6.6%

Total assets$814.9M-3.7%

Cash flow

See full

Operating cash flow-$16.8M-452%

CapEx$201.0K+93.3%

Free cash flow-$17.0M-464%

Valuation

See full

Market cap$8.58B-64.4%

Enterprise value$8.48B-65.0%

P/E181.2×+1.3×

P/S11.2×-24.0×

Profitability

See full

Gross margin98.3%-0.2pp

Operating margin-1.1%-17.2pp

Net margin6.2%-13.4pp

FCF margin15.6%-10.2pp

Returns & leverage

See full

Return on equity7.2%-14.6pp

Debt / equity0×0.0×

Current ratio2.9×-0.2×

Where this comes from

Reported directly by Corcept Therapeutics in its filing.

Tagged under the XBRL concept cort:IncreaseDecreaseInAccruedSettlementLitigationLiabilities.

The official record: Corcept Therapeutics’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Corcept Therapeutics's accrued settlement related to melucci litigation (note 10).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Corcept Therapeutics's accrued settlement related to melucci litigation (note 10)?: Corcept Therapeutics (CORT) reported accrued settlement related to melucci litigation (note 10) of $0 in Q4 2025.